HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES IN PATIENTS RECEIVING MONOCLONAL-ANTIBODY THERAPY
- 1 January 1985
- journal article
- research article
- Vol. 45 (2), 879-885
Abstract
Human anti-murine Ig responses were assessed in serum from 3 groups of patients receiving murine monoclonal antibody therapy. Each of the 3 patient groups responded differently. Chronic lymphocytic leukemia patients demonstrated little or no preexisting murine IgG reactive antiglobulin prior to treatment, while the cutaneous T-cell lymphoma and melanoma patients demonstrated preexisting antiglobulin levels in the same range as those demonstrated in healthy controls. None of 11 chronic lymphocytic leukemia patients receiving the T101 monoclonal antibody demonstrated in antiglobulin response; all 4 of the cutaneous T-cell lymphoma patients receiving the same antibody developed increased levels of antiglobulins. Three of 9 malignant melanoma patients receiving the 9.2.27 monoclonal antibody showed an increase in antiglobulin titers. In patients developing antiglobulin responses, the response was rapid, typically being detectable within 2 wk. The antiglobulins were primarily IgG and, with the exception of a single melanoma patient in whom the response appeared to have a substantial 9.2.27-specific component (i.e., antiidiotype), were cross-reactive with most murine IgG preparations tested. This pattern of results suggested that the antiglobulin was a secondary immune reaction with elevation of the levels of preexisting antiglobulin which was cross-reactive with the mouse antibody administered. While the presence of serum antiglobulin would be expected to present major complications to monoclonal antibody therapy, no clinical toxicity related to antiglobulin responses was observed in these patients, and no inhibition of antibody localization on tumor cells was seen.This publication has 10 references indexed in Scilit:
- Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration.Journal of Clinical Oncology, 1984
- EFFECTS OF MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA1984
- EFFECTS OF MONOCLONAL-ANTIBODY IMMUNOTHERAPY ON PATIENTS WITH GASTROINTESTINAL ADENOCARCINOMA1984
- Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?Proceedings of the National Academy of Sciences, 1984
- MONOCLONAL-ANTIBODY THERAPEUTIC TRIALS IN 7 PATIENTS WITH T-CELL LYMPHOMA1983
- RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODYThe Lancet, 1981
- INVIVO EFFECTS OF MURINE HYBRIDOMA MONOCLONAL-ANTIBODY IN A PATIENT WITH T-CELL LEUKEMIA1981
- SEROTHERAPY OF ACUTE LYMPHOBLASTIC-LEUKEMIA WITH MONOCLONAL-ANTIBODY1981
- Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin.The Journal of Immunology, 1980
- Antiglobulin factors in sera from patients with rheumatoid arthritis and normal subjects. Quantitative estimation in different immunoglobulin classes.Annals Of The Rheumatic Diseases, 1967